1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis

Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis

  • May 2013
  • -
  • Industry Standard Research
  • -
  • 60 pages

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the hepatocellular carcinoma (liver cancer) market not available elsewhere.

The purpose of this report is to give an extensive overview of the current and future liver cancer market, the activities of the key market players and the issues surrounding drug development.

What you will learn in this report:

• Global and country-specific incidence rates for hepatocellular carcinoma.
• Active development pipeline, including promising new therapies currently in both
Late Phase and Early Phase development
• Country-specific analysis of clinical trial environments for new hepatocellular carcinoma therapies

How you can use this report:

• Learn how products currently in the pipeline could compete in this market where the unmet need is high
• Identify strategic development opportunities
• Enhance commercialization strategic planning
• Assess competition with a full analysis and summary of companies playing in this space

Regions analyzed:

Brazil, China, France, Germany, India, Italy, Japan, Russia, South Korea, Spain, United Kingdom, and United States

Valuable for:

Brand Managers, Portfolio Managers, Research & Development, Managed Markets

Table Of Contents

Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis
Table of Contents

Copyright and Usage Guidelines 5
Table of Abbreviations 6
Table of Definitions 7
Infographic 8
Chapter 1. Hepatocellular Carcinoma Overview 9
Chapter 2. Commercial Rationale 11
High Unmet Need and Limited Available Therapies 11
Increasing HCC Incidence 14
Orphan Disease Status 14
Active Drug Development Field 15
Chapter 3. Environmental Analysis 16
Disease Epidemiology 16
Major Markets Environmental Analysis 18
Emerging Markets Environmental Analysis 23
Additional Countries 27
Chapter 4. Clinical Development Pipeline 28
RandD Trends in the Treatment of Primary Liver Cancer 28
Late Phase Development Pipeline 31
Aptocine (talaporfin sodium), Light Sciences Oncology 32
Everolimus, Novartis 33
Muparfostat, Medigen Biotech 34
ADI-PEG20, Polaris Group 35
Ramucirumab (IMC-1121B), Lilly (Imclone) 36
Tivantinib (ARQ197), ArQule and Daiichi Sankyo 37
Regorafenib (BAY73-4506), Bayer 38
Orantinib (TSU-68), Taiho Pharma 39
Peretinoin (NIK-333), Kowa 39
Resminostat, 4SC Ag 40
Early Phase Development Pipeline 41
Chapter 5. Clinical Trial Environment 43
Chapter 6. Country Profiles 47
United States 47
United Kingdom 48
France 49
Germany 50
Italy 51
Spain 52
Japan 53
Brazil 54
Russia 55
India 56
China 57
South Korea 58
Bibliography 59
About Industry Standard Research 60



List of Tables

Table 1. HCC Life Expectancy by Disease Stage 9
Table 2. BCLC HCC Classification 11
Table 3. AJCC HCC Classification 12
Table 4. Summary of SHARP Trial Results 13
Table 5. Percent of HCC Cases Linked to Risk Factors by Region 18
Table 6. Primary Liver Cancer - Major Markets Patient Population and Product Environment 19
Table 7. Primary Liver Cancer - Emerging Markets Patient Population and Product Environment 23
Table 8. The Late Phase HCC Pipeline. 31
Table 9. Overview of LitX 32
Table 10. Overview of Everolimus 33
Table 11. Overview of Muparfostat 34
Table 12. Overview of ADI-PEG20 35
Table 13. Overview of Ramucirumab 36
Table 14. Overview of Tivantinib 37
Table 15. Overview of Regorafenib 38
Table 16. Overview of Orantinib 39
Table 17. Overview of Resminostat 40
Table 18. Early Phase HCC Development Pipeline 41
Table 19. HCC Trials by Development Phase and Sponsor Type 44
Table 20. Ongoing, Industry Sponsored HCC Trials 45
Table 21. Recently Completed, Industry Sponsored HCC Trials 45
Table 22. Ongoing, All Sponsors HCC Trials 46
Table 23. Recently Completed, All Sponsors HCC Trials 46



List of Figures

Figure 1. Global Prevalence of Hepatitis B 16
Figure 2. Global Distribution of Hepatitis C 17
Figure 3. Countries with the Highest Populations of HCC Patients (2008) [5] 27


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.